News & Events
-
January 7, 2016
Best Practices for ePRO Implementation in Clinical Trials
This webinar provides an overview of considerations in selecting the optimal ePRO modes, review best practices related to the deployment of ePRO systems, and discuss key items for ePRO deployment in clinical trials. Presenters: Serge Bodart, MS (Biomedical Systems) and Elisa Holzbaur, BS, PMP (Almac) PDF version ... -
November 21, 2015
El Tour de Tucson, 2015
C-Path cycling team rides annually in the El Tour de Tucson bicycling event along with Carl Ames, PD advocate, cyclist and friend of C-Path. Carl won the buddy hero award at the Davis Phinney Victory Summit in 2013 for his role in helping the most number of people living with PD.... -
October 20, 2015
Parkinson’s UK Receives CAMD Nonprofit Organization Award
Dr. Arthur Roach, Director of Research at Parkinson’s UK accepts the first Nonprofit Organization Award from CAMD presented by Dr. Diane Stephenson, Critical Path Institute, at the annual meeting held at FDA on Oct 20th, 2015. Parkinson’s UK is recognized for their leadership in supporting the launch of a fully dedicated consortium aimed at integrating...... -
October 15, 2015
Coalition Against Major Diseases and FDA 2015 Annual Scientific Workshop
October 15, 2015 FDA White Oak Campus CO-SPONSORED BY: Critical Path Institute U.S. Food and Drug Administration Overview and Objectives The Coalition Against Major Diseases (CAMD) is a public-private-partnership aimed at creating new tools and methods that can be applied to increase the efficiency of the development process of new treatments for Alzheimer’s disease...... -
October 7, 2015
PD Imaging Biomarker Team at European Medicines Agency (EMA)
Experts of the Parkinson’s disease imaging biomarker team participated in a Scientific Advice meeting at the European Medicines Agency on October 7th 2015. The purpose of this meeting was to review the evidence provided to the Agency that supports the use of Molecular Imaging of the Dopamine Transporter as an enrichment biomarker in clinical trials......